These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30449633)

  • 1. Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.
    Dong B; Wang L; Nie S; Li X; Xiao Y; Yang L; Meng X; Zhao P; Cui C; Tu L; Lu W; Sun W; Yu Y
    Vaccine; 2018 Dec; 36(52):8148-8157. PubMed ID: 30449633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
    Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
    J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
    Kawahara M; Takaku H
    Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice.
    Tu L; Wang Z; Yang L; Sun X; Yao Y; Zhang P; Zhang X; Wang L; Yu Y; Yang M
    Front Immunol; 2023; 14():1013342. PubMed ID: 36776837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
    Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
    PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
    Murphy KA; Erickson JR; Johnson CS; Seiler CE; Bedi J; Hu P; Pluhar GE; Epstein AL; Ohlfest JR
    J Immunol; 2014 Jan; 192(1):224-33. PubMed ID: 24293627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
    Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
    Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.
    Wang X; Lu XL; Zhao HY; Zhang FC; Jiang XB
    Cancer Immunol Immunother; 2013 Jul; 62(7):1261-72. PubMed ID: 23640602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
    Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
    Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.
    Blaszczyk-Thurin M; Ertl IO; Ertl HC
    Scand J Immunol; 2002 Oct; 56(4):361-75. PubMed ID: 12234257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
    Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
    Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.
    Ueda R; Kinoshita E; Ito R; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2008 May; 122(10):2274-9. PubMed ID: 18224680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
    Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
    Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Jahan N; Talat H; Curry WT
    Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.